ASHLEY EDGAR: Open Payments
NPI 1952009573 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$929 in 45 payments from 17 companies in 2025. Trend: 2023 $98 · 2024 $1,478 · 2025 $929
Food & beverage: $929
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 9 | $205 |
| Amgen Inc. | 13 | $166 |
| PFIZER INC. | 3 | $118 |
| GENZYME CORPORATION | 3 | $88 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
| SpringWorks Therapeutics, Inc. | 2 | $44 |
| ACADIA Pharmaceuticals Inc | 2 | $39 |
| Boston Scientific Corporation | 1 | $26 |
| AstraZeneca Pharmaceuticals LP | 1 | $24 |
Products named: REPATHA, Briviact, ZAVZPRET, Fintepla, Symbravo, LEQVIO, GOMEKLI, FABRAZYME.
Industry payments across TX — which companies pay providers there.
